Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology and En...
January 31 2018 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced the publication of a
preclinical study using magnetic resource imaging (MRI) to follow
cancer peptide uptake in tumor models, and to correlate this immune
activation to the resulting anti-cancer T cell activity. The
Journal of Biomedical Science study, titled “Unique Depot Formed by
an Oil Based Vaccine Facilitates Active Antigen Uptake and Provides
Effective Tumour Control,” compared the mechanism of action (MOA)
of Immunovaccine’s platform for immunotherapeutic stimulation with
other technologies.i
In the study, published on January 27, 2018, researchers tracked
how the cancer peptides were trafficked from the injection site to
immunogenic activation in the lymph nodes. Researchers correlated
this to both activation of T cells and the ensuing efficacy to
control tumor progression. They concluded that Immunovaccine’s
delivery technology had a fundamentally unique MOA. This MOA
enabled active and prolonged immune stimulation, as well as better
tumor control, as compared to other technologies examined in the
study.
“These findings demonstrate why we’re able to generate sustained
immune system activation, and also why measuring the level of
immunogenicity at a single point in time is often not predictive of
anti-cancer activity,” said Marianne Stanford, Immunovaccine Vice
President, Research and senior author of the study. “Our approach
to generating immune responses did not follow the pattern described
for classical vaccines, in which a peak primary immune response
rapidly subsides and requires secondary stimulation for protection.
Instead, T cell activation induced by our technology is correlated
with both prolonged traffic to lymph nodes, and enhanced efficacy
in preventing tumor progression.”
One of the key findings of the study is the fundamentally unique
method by which Immunovaccine’s technology delivers
immune-activating agents, such as cancer peptides, to the immune
system. Unlike other technologies that rely on a slow release of
antigens at the site of injection, Immunovaccine’s delivery
formulation entraps the immuno-stimulating agents at the injection
site. This ‘depot’ effect forces an active uptake by immune cells,
rather than a passive diffusion at the injection site. Hence, the
immune-stimulating components are protected from degradation, are
delivered over a prolonged period of time to antigen-presenting
cells, and are actively transported to the lymph nodes.
“In this publication, we have shown that enhanced tumor control
can be correlated with our unique MOA in tumor models, which
provides insight as to why our technology may be able to provide
anti-cancer responses that have not yet been associated with other
approaches,” said Frederic Ors, Immunovaccine’s Chief Executive
Officer. “Effective T cell responses have been linked to clinical
benefits of successful cancer immunotherapies. We believe that by
generating a prolonged in vivo T cell targeted attacks on cancer
cells, our technology represents a promising alternative to ex vivo
programming of T cells, such as those associated with CAR T
therapies.”
Immunovaccine conducted the study in collaboration with BIOTIC,
a hospital-based medical imaging research centre in Halifax, Nova
Scotia. Immunovaccine previously announced findings from its BIOTIC
collaboration in 2015.
About ImmunovaccineImmunovaccine Inc. is a
clinical-stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and infectious diseases.
Immunovaccine is developing T cell-activating cancer
immunotherapies based on its patented immuno-stimulating technology
platform, which provides controlled and prolonged delivery of
immuno-stimulating agents to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase 1 human clinical trials, and is currently
conducting multiple Phase 1b and Phase 2 studies with Incyte
Corporation and Merck. These studies assessing lead
candidate, DPX-Survivac, as a combination therapy in ovarian
cancer and diffuse large B cell lymphoma. The Company is also
exploring additional applications of its platform for infectious
diseases and other therapeutic areas. DPX-RSV is an innovative
vaccine candidate for respiratory syncytial virus (RSV), which has
recently completed a Phase 1 clinical trial. Connect at
www.imvaccine.com.
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E:
info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
___________________________
i Published online, January 27, 2018. DOI:
10.1186/s12929-018-0413-9
IMV (TSX:IMV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMV (TSX:IMV)
Historical Stock Chart
From Apr 2023 to Apr 2024